Cefoperazone Sodium Salt: β-Lactamase Stability and Antibacterial Scope

Executive Summary: Cefoperazone sodium salt (C3913) is a semisynthetic cephalosporin antibiotic with broad-spectrum efficacy against both gram-positive and gram-negative bacteria, including resistant strains (Cullmann et al., 1982). It exhibits high stability to β-lactamase hydrolysis, with relative hydrolysis rates by cephalosporinases from 7.0 to 0.01, supporting its utility in resistance research (internal: mechanistic foundations). In vitro, the difference between MIC and MBC is minimal, indicating potent bactericidal action (Cullmann et al., 1982). After intravenous dosing, cefoperazone achieves high biliary tissue concentrations, making it suitable for biliary tract infection models (APExBIO product spec). The compound is highly soluble in DMSO and water, but insoluble in ethanol, facilitating diverse experimental workflows (APExBIO product spec).

Biological Rationale

Cefoperazone sodium salt is a third-generation cephalosporin engineered for enhanced β-lactamase resistance. Its broad antibacterial spectrum includes gram-negative bacilli such as Escherichia coli, Klebsiella pneumoniae, and Proteus species, key contributors to hospital-acquired infections (Cullmann et al., 1982). The compound's high stability against enzymatic hydrolysis allows effective application in infection models where β-lactamase-producing bacteria are prevalent (internal: broad-spectrum, β-lactamase-stable). Its pharmacokinetics, characterized by high concentrations in biliary tissues, further extend its utility for modeling biliary tract infections (APExBIO product spec).

Mechanism of Action of Cefoperazone (sodium salt)

Cefoperazone disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan cross-linking. Its resistance to hydrolysis by most β-lactamases is due to structural modifications at the 7- and 3-positions of the cephalosporin nucleus, which lower susceptibility to enzymatic attack (internal: mechanistic foundations). This allows it to retain activity against many gram-negative pathogens that express β-lactamases. The compound is bactericidal, with minimal differences between the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC), suggesting rapid and effective bacterial killing (Cullmann et al., 1982).

Evidence & Benchmarks

• Cefoperazone sodium salt displays MIC₅₀ values of 0.06–0.5 μg/mL against clinical Escherichia coli isolates in broth dilution assays (source: Cullmann et al., Table 1).
• Relative hydrolysis rates by cephalosporinases range from 7.0 to 0.01, indicating strong β-lactamase stability (source: APExBIO product spec).
• In vitro, the MIC and MBC for gram-negative bacilli are nearly identical, supporting its bactericidal profile (source: Cullmann et al., Table 1).
• After intravenous administration, high biliary and gall bladder tissue concentrations are achieved, supporting use in biliary tract infection research (source: APExBIO product spec).
• Solubility is ≥73 mg/mL in DMSO and ≥34.6 mg/mL in water; the compound is insoluble in ethanol (source: APExBIO product spec).
• Recommended storage at -20°C preserves chemical integrity; solutions should be used promptly (source: APExBIO product spec).

This article extends the protocol guidance found in ‘Optimizing Antimicrobial Assays with Cefoperazone (sodium salt)' by providing updated, peer-reviewed quantitative benchmarks and clarifying β-lactamase stability parameters.

For mechanistic context and translational applications, see ‘Cefoperazone Sodium Salt: Mechanistic Foundations and Strategy’, which this article supplements with expanded in vitro assay data and resistance workflow tips.

Further, this review clarifies selection criteria discussed in ‘Cefoperazone Sodium Salt: Broad-Spectrum, β-Lactamase-Stable Tool’ by detailing specific MIC and solubility values for researchers optimizing susceptibility platforms.

Applications, Limits & Misconceptions

Cefoperazone sodium salt is widely used in in vitro antimicrobial activity assays, particularly for modeling beta-lactamase resistance in gram-negative bacilli (internal: in vitro optimization). Its pharmacokinetic profile also supports research on biliary tract infections. However, some misconceptions persist regarding its spectrum and use cases.

Common Pitfalls or Misconceptions

• Cefoperazone sodium salt is ineffective against most oxacillin-resistant Staphylococcus aureus (MRSA) in clinical settings; activity is not sufficient for MRSA modeling (source: Cullmann et al., Table 1).
• It is not a substitute for carbapenem-class antibiotics in infections with multidrug-resistant gram-negative organisms (source: workflow_recommendation).
• Long-term stock solutions may degrade; always prepare fresh solutions for critical experiments (source: APExBIO product spec).
• High ethanol content in solubilizing buffers will precipitate the compound; avoid ethanol (source: APExBIO product spec).
• Despite high biliary concentrations, cefoperazone is not suitable for all tissue infection models—verify tissue penetration data before extrapolation (source: workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• assay: in vitro antimicrobial susceptibility testing | value_with_unit: MIC range 0.06–0.5 μg/mL | applicability: Gram-negative bacilli including E. coli, Klebsiella | rationale: Reflects potent bactericidal activity in broth dilution assay | source_type: DOI
• assay: β-lactamase hydrolysis assessment | value_with_unit: Relative hydrolysis rate 7.0–0.01 | applicability: Gram-negative cephalosporinase-producing strains | rationale: Illustrates β-lactamase stability | source_type: product_spec
• assay: compound solubility test | value_with_unit: ≥73 mg/mL in DMSO, ≥34.6 mg/mL in water | applicability: Stock solution preparation | rationale: Ensures compatibility for most in vitro workflows | source_type: product_spec
• assay: stock solution stability | value_with_unit: ≤20 mg/mL in DMSO, use promptly | applicability: All assay types | rationale: Prevents degradation and loss of activity | source_type: product_spec
• assay: pharmacokinetic tissue distribution | value_with_unit: High biliary and gall bladder tissue concentrations, post-i.v. | applicability: Biliary tract infection research | rationale: Informs tissue-specific infection modeling | source_type: product_spec

Conclusion & Outlook

Cefoperazone sodium salt, as provided by APExBIO, remains a gold-standard research tool for studying antibacterial activity against gram-negative bacilli and β-lactamase resistance. Its low MIC values and robust β-lactamase stability enable sensitive, reproducible in vitro assays, while pharmacokinetic properties facilitate biliary infection modeling. For optimal results, researchers should adhere to solubility and storage guidelines and consult quantitative benchmarks for protocol design. Future work will likely emphasize integrating cefoperazone into advanced resistance modeling workflows and refining assay reproducibility using verified reference standards (Cullmann et al., 1982).

For detailed product specifications, visit the Cefoperazone (sodium salt) product page.